LINK Medical possesses the expertise and resources to advance your drug from first-in-human (FIH) studies to proof of concept.
Whether you need to test your new compound in cohorts of healthy volunteers or patients at single ascending doses (SAD study), to explore multiple ascending doses (MAD study), or conduct other Phase I studies, our collaborations with multiple approved Phase I clinics in various countries allow us to match each study with the most suitable clinic.
LINK Medical also handles early clinical studies, (including FIH studies), with oncology compounds or other toxic compounds. Therefor we collaborate with specialized clinics that can treat these severely ill patients and handle complex studies.
Contact us for consultation on study design approaches, selecting the right clinical setting, and establishing clinical study protocols for Phase I studies.